Asuragen
Company

Last deal

$7.5M

Amount

Venture - Series Unknown

Stage

20.03.2013

Date

5

all rounds

$80M

Total amount

General

About Company
Asuragen is a fully integrated diagnostics company specializing in mRNA-based solutions for molecular oncology and early cancer detection.

Industry

Sector :

Subsector :

founded date

01.01.2006

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

With a focus on microRNA, Asuragen offers a comprehensive portfolio of Signature® Genetic and Oncology Testing products, along with industry-leading controls and standards developed using its patented Armored RNA® technology. In addition to diagnostics, Asuragen provides GLP testing services and operates a cGMP manufacturing facility, enabling them to cover the entire spectrum of discovery, testing, production, and commercialization. As a Bio-Techne brand, Asuragen is revolutionizing genetics and oncology treatment by delivering powerful diagnostic systems that utilize proprietary chemistry and software, compatible with widely used instrument platforms. Their user-friendly solutions enhance patient care, addressing various clinical needs such as cancer diagnosis and monitoring, reproductive health, and aging, making them a trusted partner for laboratories throughout a patient's lifespan. Bio-Techne, a global life sciences company, supports Asuragen's mission by providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
Contacts

Social url